Eisai’s drug has been submitted for approval on the back of a single-arm phase 2 trial (Study 201) that enrolled patients in Japan and China with FGFR2 gene fusion-positive unresectable biliary ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Previous studies of the bile acid composition of meconium and bile obtained in the first few days of life indicate that, compared to the adult, there are significant differences in the hepatic ...